Invention Grant
- Patent Title: Fused pentacyclic imidazole derivatives as modulators of TNF activity
-
Application No.: US16086418Application Date: 2017-03-31
-
Publication No.: US10669286B2Publication Date: 2020-06-02
- Inventor: Michael Louis Robert Deligny , Jag Paul Heer
- Applicant: UCB Biopharma SRL , Sanofi
- Applicant Address: BE Brussels FR Paris
- Assignee: UCB Biopharma SRL,Sanofi
- Current Assignee: UCB Biopharma SRL,Sanofi
- Current Assignee Address: BE Brussels FR Paris
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@7693365f
- International Application: PCT/EP2017/057765 WO 20170331
- International Announcement: WO2017/167993 WO 20171005
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D519/00 ; C07D487/18 ; C07D487/22 ; A61P25/28 ; A61P37/04 ; A61P9/00 ; A61P3/10 ; A61P35/00

Abstract:
A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Public/Granted literature
- US20190119302A1 Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity Public/Granted day:2019-04-25
Information query